[1]
|
WHO (2017) Global Report on Diabetes. World Health Organization. https://www.who.int/diabetes/global-report/en/
|
[2]
|
Kang, Y.M. and Jung, C.H. (2017) Effects of Incretin-Based Therapies on Diabetic Microvascular Complications. Endocrinology and Metabolism, 32, 316-325. https://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2017.32.3.316 https://doi.org/10.3803/EnM.2017.32.3.316
|
[3]
|
Kang, Y.M. and Jung, C.H. (2016) Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinology and Metabolism, 31, 258-274. http://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2016.31.2.258 https://doi.org/10.3803/EnM.2016.31.2.258
|
[4]
|
Pratley, R.E. and Gilbert, M. (2008) Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. The Review of Diabetic Studies, 5, 73-94. https://doi.org/10.1900/RDS.2008.5.73 http://www.soc-bdr.org/content/e4/e887/volRdsVolumes5237/issRdsIssues5874/chpRdsChapters 5886/strRdsArticles5887/index_en.html?preview=preview
|
[5]
|
Conarello, S.L., Li, Z., Ronan, J., Roy, R.S., Zhu, L., Jiang, G., et al. (2003) Mice Lacking Dipeptidyl Peptidase IV Are Protected against Obesity and Insulin Resistance. Proceedings National Academy of Sciencs of the USA, 100, 6825-6830. http://www.pnas.org/cgi/doi/10.1073/pnas.0631828100 https://doi.org/10.1073/pnas.0631828100
|
[6]
|
Ben-Shlomo, S., Ben, S.S., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., et al. (2013) Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis. Digestive Diseases and Sciences, 58, 172-178. http://link.springer.com/10.1007/s10620-012-2353-7 https://doi.org/10.1007/s10620-012-2455-2
|
[7]
|
Chen, C., Yu, Q., Zhang, S., Yang, P. and Wang, C.-Y. (2015) Assessing the Efficacy and Safety of Combined DPP-4 Inhibitor and Insulin Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. International Journal of Clinical & Experimental Pathology, 8, 14141-14150. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713513/
|
[8]
|
DeFronzo, R., Triplitt, E. and Cersosimo, R.A. (2010) Pioglitazone and Alogliptin Combination Therapy in Type 2 Diabetes: A Pathophysiologically Sound Treatment. Vascular Health and Risk Management, 6, 671-690. http://www.dovepress.com/pioglitazone-and-alogliptin-combination-therapy-in-type-2-diabetes -a-p-peer-reviewed-article-VHRM https://doi.org/10.2147/VHRM.S4852
|
[9]
|
Ahren, B. (2008) Novel Combination Treatment of Type 2 Diabetes DPP-4 Inhibition + Metformin. Vascular Health and Risk Management, 4, 383-394. https://www.dovepress.com/novel-combination-treatment-of-type-2-diabetes-dpp-4-inhibition --metfo-peer-reviewed-article-VHRM https://doi.org/10.2147/VHRM.S1944
|
[10]
|
Sa-Nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., et al. (2017) SGLT2-Inhibitor and DPP-4 Inhibitor Improve Brain Function via Attenuating Mitochondrial Dysfunction, Insulin Resistance, Inflammation, and Apoptosis in HFD-Induced Obese Rats. Toxicology and Applied Pharmacology, 333, 43-50. https://doi.org/10.1016/j.taap.2017.08.005 https://linkinghub.elsevier.com/retrieve/pii/S0041008X1730340X
|
[11]
|
Wang, M.-T., Lin, S.-C., Tang, P.-L., Hung, W.-T., Cheng, C.-C., Yang, J.-S., et al. (2017) The Impact of DPP-4 Inhibitors on Long-Term Survival among Diabetic Patients after First Acute Myocardial Infarction. Cardiovasc Diabetol, 16, 89. http://cardiab.biomedcentral.com/articles/10.1186/s12933-017-0572-0 https://doi.org/10.1186/s12933-017-0572-0
|
[12]
|
Kanazawa, I., Tanaka, K. and Sugimoto, T. (2014) DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus. Medical Science Monit, 20, 1662-1667. http://www.ncbi.nlm.nih.gov/pubmed/25228119 https://doi.org/10.12659/MSM.890989
|
[13]
|
Angelopoulou, E. and Piperi, C. (2018) DPP-4 Inhibitors: A Promising Therapeutic Approach against Alzheimer’s Disease. Annals of Translational Medicine, 6, 255-255. http://atm.amegroups.com/article/view/19330/19961 https://doi.org/10.21037/atm.2018.04.41
|
[14]
|
Muriach, M., Flores-Bellver, M., Romero, F.J. and Barcia, J.M. (2014) Diabetes and the Brain: Oxidative Stress, Inflammation, and Autophagy. Oxidative Medicine and Cellular Longevity, 2014, Article ID 102158. https://doi.org/10.1155/2014/102158 http://www.ncbi.nlm.nih.gov/pubmed/25215171
|
[15]
|
El Assar, M., Angulo, J. and Rodríguez-Manas, L. (2016) Diabetes and Ageing-Induced Vascular Inflammation. The Journal of Physiology, 594, 2125-2146. http://www.ncbi.nlm.nih.gov/pubmed/26435167 https://doi.org/10.1113/JP270841
|
[16]
|
Karam, B.S., Chavez-Moreno, A., Koh, W., Akar, J.G. and Akar, F.G. (2017) Oxidative Stress and Inflammation as Central Mediators of Atrial Fibrillation in Obesity and Diabetes. Cardiovascular Diabetology, 16, 120. http://www.ncbi.nlm.nih.gov/pubmed/28962617 https://doi.org/10.1186/s12933-017-0604-9
|
[17]
|
Delgado-García, G., Galarza-Delgado, D.á., Colunga-Pedraza, I., Borjas-Almaguer, O.D., Mandujano-Cruz, I., Benavides-Salgado, D., et al. (2016) O volume plaquetário médio está reduzido em adultos com lúpus ativo. Revista Brasileira de Reumatologia, 56, 504-508. http://www.ncbi.nlm.nih.gov/pubmed/26968762 https://doi.org/10.1016/j.rbr.2015.12.003
|
[18]
|
Karaman, H., Karakukcu, C. and Kocer, D. (2013) Can Mean Platelet Volume Serve as a Marker for Prostatitis? International Journal of Medical Sciences, 10, 1387-1391. http://www.ncbi.nlm.nih.gov/pubmed/23983600 https://doi.org/10.7150/ijms.6126
|
[19]
|
Beyazit, F., Oztürk, F.H., Pek, E. and ünsal, M.A. (2017) Evaluation of the Hematologic System as a Marker of Subclinical Inflammation in Hyperemesis Gravidarum: A Case Control Study. Ginekologia Polska, 88, 315-319. http://www.ncbi.nlm.nih.gov/pubmed/28727131 https://doi.org/10.5603/GP.a2017.0059
|
[20]
|
Avci, A., Avci, D., Erden, F., Ragip, E., Cetinkaya, A., Ozyurt, K., et al. (2017) Can We Use the Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume Values for the Diagnosis of Anterior Uveitis in Patients with Behcet’s Disease? Therapeutics and Clinical Risk Management, 13, 881. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529084/ https://doi.org/10.2147/TCRM.S135260
|
[21]
|
Erden, F., Karagoz, H., Avci, A., Avci, D., Cetinkaya, A. and Erden, A. (2017) The Values of Mean Platelet Volume and the Mean Platelet Volume/Platelet Ratio for Predicting Deep Venous Thrombosis in Behcet’s Disease. LaboratoriumsMedizin, 41, 153-157. https://doi.org/10.1515/labmed-2017-0068 http://www.degruyter.com/view/j/labm.2017.41.issue-3/labmed-2017-0068/labmed-2017- 0068.xml
|
[22]
|
Paolicchi, A., Minotti, G., Tonarelli, P., Tongiani, R., De Cesare, D., Mezzetti, A., et al. (1999) Gamma-Glutamyl Transpeptidase-Dependent Iron Reduction and LDL Oxidation—A Potential Mechanism in Atherosclerosis. Journal of Investigative Medicine, 47, 151-160. http://www.ncbi.nlm.nih.gov/pubmed/10198571
|
[23]
|
Kim, J.G., Chang, K., Choo, E.H., Lee, J.-M. and Seung, K.-B. (2018) Serum Gamma-Glutamyl Transferase Is a Predictor of Mortality in Patients with Acute Myocardial Infarction. Medicine (Baltimore), 97, e11393. http://www.ncbi.nlm.nih.gov/pubmed/30024510 https://doi.org/10.1097/MD.0000000000011393
|
[24]
|
Williams, M.D. and Nadler, J.L. (2007) Inflammatory Mechanisms of Diabetic Complications. Current Diabetes Reports, 7, 242-248. http://www.ncbi.nlm.nih.gov/pubmed/17547842 https://doi.org/10.1007/s11892-007-0038-y
|
[25]
|
Akoumianakis, I. and Antoniades, C. (2017) Dipeptidyl Peptidase IV Inhibitors as Novel Regulators of Vascular Disease. Vascular Pharmacology, 96-98, 1-4. https://linkinghub.elsevier.com/retrieve/pii/S1537189117301556 https://doi.org/10.1016/j.vph.2017.07.001
|
[26]
|
Duan, L., Rao, X., Xia, C., Rajagopalan, S. and Zhong, J. (2017) The Regulatory Role of DPP4 in Atherosclerotic Disease. Cardiovascular Diabetology, 16, 76. http://cardiab.biomedcentral.com/articles/10.1186/s12933-017-0558-y https://doi.org/10.1186/s12933-017-0558-y
|
[27]
|
Lontchi-Yimagou, E., Sobngwi, E., Matsha, T.E. and Kengne, A.P. (2013) Diabetes Mellitus and Inflammation. Current Diabetes Reports, 13, 435-444. http://link.springer.com/10.1007/s11892-013-0375-y https://doi.org/10.1007/s11892-013-0375-y
|
[28]
|
Xie, W., Song, X. and Liu, Z. (2018) Impact of Dipeptidyl-Peptidase 4 Inhibitors on Cardiovascular Diseases. Vascular Pharmacology, 109, 17-26. https://linkinghub.elsevier.com/retrieve/pii/S1537189117302999 https://doi.org/10.1016/j.vph.2018.05.010
|
[29]
|
Birnbaum, Y., Bajaj, M., Yang, H.-C. and Ye, Y. (2018) Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovascular Drugs and Therapy, 32, 135-145. http://link.springer.com/10.1007/s10557-018-6778-x https://doi.org/10.1007/s10557-018-6778-x
|
[30]
|
Ikedo, T., Minami, M., Kataoka, H., Hayashi, K., Nagata, M., Fujikawa, R., et al. (2017) Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation. Journal of the American Heart Association, 6. https://doi.org/10.1161/JAHA.116.004777 https://www.ahajournals.org/doi/10.1161/JAHA.116.004777
|
[31]
|
Ervinna, N., Mita, T., Yasunari, E., Azuma, K., Tanaka, R., Fujimura, S., et al. (2013) Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male Apo E-Deficient Mice. Endocrinology, 154, 1260-1270. https://academic.oup.com/endo/article-lookup/doi/10.1210/en.2012-1855 https://doi.org/10.1210/en.2012-1855
|
[32]
|
Singh, T.P., Vangaveti, V.N. and Malabu, U.H. (2015) Dipeptidyl Peptidase-4 Inhibitors and Their Potential Role in the Management of Atherosclerosis—A Review. Diabetology & Metabolic Syndrome, 9, 223-229. https://linkinghub.elsevier.com/retrieve/pii/S1871402115000338 https://doi.org/10.1016/j.dsx.2015.04.005
|
[33]
|
Tanju, C., Ekrem, G., Berksoy Emel, A. and Nur, A. (2014) Mean Platelet Volume as a Negative Marker of Inflammation in Children with Rotavirus Gastroenteritis. Iranian Journal of Pediatrics, 24, 617-622. http://www.ncbi.nlm.nih.gov/pubmed/25793071
|
[34]
|
Kodiatte, T.A., Manikyam, U.K., Rao, S.B., Jagadish, T.M., Reddy, M., Lingaiah, H.K.M., et al. (2012) Mean Platelet Volume in Type 2 Diabetes Mellitus. Journal of Laboratory Physicians, 4, 5-9. http://www.jlponline.org/text.asp?2012/4/1/5/98662 https://doi.org/10.4103/0974-2727.98662
|
[35]
|
Papanas, N., Symeonidis, G., Maltezos, E., Mavridis, G., Karavageli, E., Vosnakidis, T., et al. (2004) Mean Platelet Volume in Patients with Type 2 Diabetes Mellitus. Platelets, 15, 475-458. https://doi.org/10.1080/0953710042000267707 http://www.tandfonline.com/doi/full/10.1080/0953710042000267707
|
[36]
|
Aksu, E., Avci, D. and Cikim, G. (2016) The Relation between Mean Platelet Volume and Coronary Artery Disease in Type 2 Diabetes Mellitus Patients. International Journal of Health Sciences and Research, 6, 50. http://www.ijhsr.org
|
[37]
|
Hudzik, B., Korzonek-Szlacheta, I., Szkodziński, J., Liszka, R., Lekston, A., Zubelewicz-Szkodzińska, B., et al. (2018) Association between Multimorbidity and Mean Platelet Volume in Diabetic Patients with Acute Myocardial Infarction. Acta Diabetologica, 55, 175-183. http://link.springer.com/10.1007/s00592-017-1079-6 https://doi.org/10.1007/s00592-017-1079-6
|
[38]
|
Sarikaya, S., Sahin, S., Akyol, L., Borekci, E., Yilmaz, Y.K., Altunkas, F., et al. (2014) Mean Platelet Volume Is Associated with Myocardial Perfusion Defect in Diabetic Patients. Cardiovascular Journal of Africa, 25, 110-113. http://www.cvja.co.za/onlinejournal/vol25/vol25_issue3/#20/z https://doi.org/10.5830/CVJA-2014-013
|
[39]
|
Ulutas, K.T., Dokuyucu, R., Sefil, F., Yengil, E., Sumbul, A.T., Rizaoglu, H., et al. (2014) Evaluation of Mean Platelet Volume in Patients with Type 2 Diabetes Mellitus and Blood Glucose Regulation: A Marker for Atherosclerosis? International Journal of Clinical and Experimental Medicine, 7, 955-961. http://www.ncbi.nlm.nih.gov/pubmed/24955167
|
[40]
|
Ceyhun, V.A.R.I.M., et al. (2015) Yeni Tani Tip 2 Diabetes Mellitus’ lu hastalarda DPP-4 inhibitorlerinin HbA1c, Hematolojik ve Inflamasyon Parametreleri Uzerine Etkileri. Ortadogu Medical Journal, 7, 172-177. https://web.a.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype= crawler&jrnl=13093630&AN=112699282&h=rfRulFY0B7CU1J8CQsSO6WI11pDAl 7p70IYfyBQpSyUAbeFELlAFuPWCeO3B82ybfTxztGdZ%2FKNT6lihdy7Ayg%3D%3D &crl=c&resultNs=AdminWebAuth&resultLocal
|
[41]
|
Goldberg, D.M. (1980) Structural, Functional, and Clinical Aspects of Gamma-Glutamyltransferase. CRC Critical Reviews in Clinical Laboratory Sciences, 12, 1-58. http://www.ncbi.nlm.nih.gov/pubmed/6104563 https://doi.org/10.3109/10408368009108725
|
[42]
|
Ali, S.S., Oni, E.T., Blaha, M.J., Veledar, E., Feiz, H.R., Feldman, T., et al. (2016) Elevated Gamma-Glutamyl Transferase Is Associated with Subclinical Inflammation Independent of Cardiometabolic Risk Factors in an Asymptomatic Population: A Cross-Sectional Study. Nutrition & Metabolism, 13, 37. http://www.ncbi.nlm.nih.gov/pubmed/27195017 https://doi.org/10.1186/s12986-016-0097-7
|
[43]
|
Lee, D.S., Evans, J.C., Robins, S.J., Wilson, P.W., Albano, I., Fox, C.S., et al. (2007) Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk: The Framingham Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 127-133. https://doi.org/10.1161/01.ATV.0000251993.20372.40 https://www.ahajournals.org/doi/10.1161/01.ATV.0000251993.20372.40
|
[44]
|
Ortakoyluoglu, A., Boz, B., Dizdar, O.S., Avci, D., Cetinkaya, A. and Baspinar, O. (2016) The Association of Serum Gamma-Glutamyl Transpeptidase Level and Other Laboratory Parameters with Blood Pressure in Hypertensive Patients under Ambulatory Blood Pressure Monitoring. Therapeutics and Clinical Risk Management, 12, 1395-1401. https://doi.org/10.2147/TCRM.S116603 https://www.dovepress.com/the-association-of-serum-gamma-glutamyl-transpeptidase-level- and-other-peer-reviewed-article-TCRM
|
[45]
|
El-Sherbeeny, N.A. and Nader, M.A. (2016) The Protective Effect of Vildagliptin in Chronic Experimental Cyclosporine A-Induced Hepatotoxicity. Canadian Journal of Physiology and Pharmacology, 94, 251-256. http://www.nrcresearchpress.com/doi/10.1139/cjpp-2015-0336 https://doi.org/10.1139/cjpp-2015-0336
|
[46]
|
Osawa, S., Kawamori, D., Katakami, N., Takahara, M., Sakamoto, F., Katsura, T., et al. (2016) Significant Elevation of Serum Dipeptidyl Peptidase-4 Activity in Young-Adult Type 1 Diabetes. Diabetes Research and Clinical Practice, 113, 135-142. https://doi.org/10.1016/j.diabres.2015.12.022 https://linkinghub.elsevier.com/retrieve/pii/S0168822716000309
|
[47]
|
Gupta, N.A., Mells, J., Dunham, R.M., Grakoui, A., Handy, J., Saxena, N.K., et al. (2010) Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway. Hepatology, 51, 1584-1592. https://doi.org/10.1002/hep.23569
|
[48]
|
Yilmaz, Y., Yonal, O., Deyneli, O., Celikel, C.A., Kalayci, C. and Duman, D.G. (2012) Effects of Sitagliptin in Diabetic Patients with Nonalcoholic Steatohepatitis. Acta Gastro-Enterologica Belgica, 75, 240-244. http://www.ncbi.nlm.nih.gov/pubmed/22870790
|
[49]
|
Atil, A. and Deniz, A. (2018) Could Be Serum Uric Acid a Risk Factor for Thrombosis and/or Uveitis in Behcet’s Disease? Vascular, 26, 378-386. http://journals.sagepub.com/doi/10.1177/1708538117742831 https://doi.org/10.1177/1708538117742831
|
[50]
|
Jensen, T., Niwa, K., Hisatome, I., Kanbay, M., Andres-Hernando, A., Roncal-Jimenez, C.A., et al. (2018) Increased Serum Uric Acid over Five Years Is a Risk Factor for Developing Fatty Liver. Scientific Reports, 8, Article No. 11735. http://www.nature.com/articles/s41598-018-30267-2 https://doi.org/10.1038/s41598-018-30267-2
|
[51]
|
Yamagishi, S., Ishibashi, Y., Ojima, A, Sugiura, T. and Matsui, T. (2014) Linagliptin, a Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients Partly by Suppressing Xanthine Oxidase Activity. International Journal of Cardiology, 176, 550-552. https://linkinghub.elsevier.com/retrieve/pii/S0167527314012157 https://doi.org/10.1016/j.ijcard.2014.07.023
|
[52]
|
Moriya, C. and Satoh, H. (2016) Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats. Journal of Diabetes Research, 2016, Article ID: 3201534. http://www.hindawi.com/journals/jdr/2016/3201534/ https://doi.org/10.1155/2016/3201534
|
[53]
|
Shimodaira, M., Niwa, T., Nakajima, K. and Kobayashi, M. (2015) Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes. Endocrine, Metabolic & Immune Disorders—Drug Targets, 15, 223-228. http://www.ncbi.nlm.nih.gov/pubmed/25809193 https://doi.org/10.2174/1871530315666150324114149
|